10 years down

the line: Long

term Strategy
of Nucleon


Developing new
partnerships is an
important strategy for the
continued growth and
success of Nucleon
Increasing the
availability of resources,
expanding capabilities
and strengthening
internal research and
development.
Due to its small size,
Nucleon needs to
carefully select its
portfolio of projects.
Suggestions

Nucleon to base its
product pipeline on
the following criteria:
There is an unmet
medical need
There is a chance to
achieve a dominant
proprietary positions
There are
predictable
preclinical models
The used technology
adds value
The cell lines can be
scaled-up
Nucleon should
evolve into an R&D
boutique with pilot
scale manufacturing
capabilities.
The revenue in form
of royalties from the
diverse therapeutic
application of the
CRP-1 molecule
would accelerate the
in-house development
of the other molecules
and of the mammalian
cells technology.
Focus on developing a mammalian cells technology, which makes
developing biologics faster, easier, safer and more cost-effective
than the conventional bacterial cells method.
Nucleon will have to continuously improve its innovative
technology; therefore it is necessary to build a pilot plant
designed to manufacture products using mammalian cells
fermentation;
This will give it a competitive advantage on the other companies
using the traditional technology.